Cosmo Pharmaceuticals N.V (F:C43) — Market Cap & Net Worth
Market Cap & Net Worth: Cosmo Pharmaceuticals N.V (C43)
Cosmo Pharmaceuticals N.V (F:C43) has a market capitalization of $993.61 Million (€849.89 Million) as of September 19, 2026. Listed on the F stock exchange, this Germany-based company holds position #8977 globally and #1150 in its home market, demonstrating a -5.47% decrease in market value over the past year.
Market capitalization, also known as net worth in stock markets, is calculated by multiplying Cosmo Pharmaceuticals N.V's stock price €55.30 by its total outstanding shares 17190494 (17.19 Million). Also see Cosmo Pharmaceuticals N.V balance sheet assets for a full breakdown of the balance sheet.
Cosmo Pharmaceuticals N.V Market Cap History: 2015 to 2026
Cosmo Pharmaceuticals N.V's market capitalization history from 2015 to 2026. Data shows change from $2.64 Billion to $1.11 Billion (-6.84% CAGR). Also see cash flow conversion of Cosmo Pharmaceuticals N.V for how efficiently the company converts equity into cash flow.
Cosmo Pharmaceuticals N.V Market Cap to Earnings & Revenue Ratios Timeline
This chart shows how Cosmo Pharmaceuticals N.V's valuation ratios have evolved. The Price to Sales (P/S) ratio compares market cap to revenue, while the Price to Earnings (P/E) ratio compares market cap to net income. Lower values may indicate a more undervalued company relative to its financial performance. Check today's stock price for Cosmo Pharmaceuticals N.V for real-time trading data and today's change.
Latest Price to Sales (P/S) Ratio
21.80x
Cosmo Pharmaceuticals N.V's market cap is 21.80 times its annual revenue
Latest Price to Earnings (P/E) Ratio
N/A
P/E ratio not applicable due to negative or zero earnings
What These Ratios Tell Investors:
- Price to Sales (P/S) Ratio: Shows how much investors are paying for each dollar of the company's sales. Lower P/S ratios may indicate undervaluation.
- Price to Earnings (P/E) Ratio: Shows how much investors are paying for each dollar of the company's earnings. This is one of the most common valuation metrics.
- Trends in these ratios over time can indicate changing investor sentiment about the company's future growth prospects.
- Industry comparison provides context for whether the company is valued higher or lower than peers.
| Year | Market Cap (USD) | Revenue (USD) | Net Income (USD) | P/S Ratio | P/E Ratio |
|---|---|---|---|---|---|
| 2016 | $2.84 Billion | $67.66 Million | $19.34 Million | 42.04x | 147.09x |
| 2017 | $2.26 Billion | $67.24 Million | -$32.45 Million | 33.66x | N/A |
| 2018 | $1.43 Billion | $65.62 Million | -$18.01 Million | 21.74x | N/A |
| 2019 | $1.27 Billion | $62.49 Million | -$24.42 Million | 20.29x | N/A |
| 2020 | $1.40 Billion | $60.95 Million | -$7.90 Million | 23.05x | N/A |
| 2021 | $1.13 Billion | $65.07 Million | $21.67 Million | 17.38x | 52.19x |
| 2022 | $1.15 Billion | $102.09 Million | $17.23 Million | 11.29x | 66.93x |
| 2023 | $1.04 Billion | $92.78 Million | -$10.78 Million | 11.16x | N/A |
| 2024 | $1.36 Billion | $266.79 Million | $133.24 Million | 5.08x | 10.18x |
| 2025 | $2.27 Billion | $104.17 Million | -$3.61 Million | 21.80x | N/A |
Competitor Companies of C43 by Market Capitalization
Companies near Cosmo Pharmaceuticals N.V in the global market cap rankings as of September 19, 2026. Review tangible equity quality of Cosmo Pharmaceuticals N.V to assess the quality of the company's equity after excluding intangible assets.
Key companies related to Cosmo Pharmaceuticals N.V by market ranking:
- Eli Lilly and Company (NYSE:LLY): Ranked #16 globally with a market cap of $1.03 Trillion USD.
- Eli Lilly and Company (SA:LILY34): Ranked #20 globally with a market cap of $853.51 Billion USD ( R$4.35 Trillion BRL).
- Johnson & Johnson (NYSE:JNJ): Ranked #29 globally with a market cap of $574.95 Billion USD.
- AbbVie Inc (NYSE:ABBV): Ranked #45 globally with a market cap of $356.49 Billion USD.
| Rank | Company | Symbol | Market Cap | Price |
|---|---|---|---|---|
| #16 | Eli Lilly and Company | NYSE:LLY | $1.03 Trillion | $1152.93 |
| #20 | Eli Lilly and Company | SA:LILY34 | $853.51 Billion | R$153.70 |
| #29 | Johnson & Johnson | NYSE:JNJ | $574.95 Billion | $269.99 |
| #45 | AbbVie Inc | NYSE:ABBV | $356.49 Billion | $263.96 |
Cosmo Pharmaceuticals N.V Historical Marketcap From 2015 to 2026
Between 2015 and today, Cosmo Pharmaceuticals N.V's market cap moved from $2.64 Billion to $ 1.11 Billion, with a yearly change of -6.84%.
| Year | Market Cap | Change (%) |
|---|---|---|
| 2026 | €1.11 Billion | -51.06% |
| 2025 | €2.27 Billion | +67.41% |
| 2024 | €1.36 Billion | +31.06% |
| 2023 | €1.04 Billion | -10.21% |
| 2022 | €1.15 Billion | +1.92% |
| 2021 | €1.13 Billion | -19.48% |
| 2020 | €1.40 Billion | +10.79% |
| 2019 | €1.27 Billion | -11.13% |
| 2018 | €1.43 Billion | -36.96% |
| 2017 | €2.26 Billion | -20.44% |
| 2016 | €2.84 Billion | +7.95% |
| 2015 | €2.64 Billion | -- |
End of Day Market Cap According to Different Sources
On Sep 19th, 2026 the market cap of Cosmo Pharmaceuticals N.V was reported to be:
| Source | Market Cap |
|---|---|
| Yahoo Finance | $993.61 Million USD |
| MoneyControl | $993.61 Million USD |
| MarketWatch | $993.61 Million USD |
| marketcap.company | $993.61 Million USD |
| Reuters | $993.61 Million USD |
Market cap values may vary slightly between sources due to differences in calculation methods, timing, and data refresh rates.
About Cosmo Pharmaceuticals N.V
Cosmo N.V., a life sciences company, develops and manufactures pharmaceuticals and contracts for gastroenterology, dermatology, and health tech in Ireland and internationally. The company offers GI Genius, a computer-assisted system that uses artificial intelligence in real time to detect colorectal lesions; Winlevi, a prescription medicine used on the skin to treat acne vulgaris; Lialda/Mezavant… Read more